1. Insulinotropic potency of glipizide in vitro

   • A. Herchuelz
   • W. J. Malaisse

   OriginalPaper Pages: 309 - 310

2. Pharmacodynamic aspects of two sulphonylurea derivatives glipizide and glibenclamide

   • D. Artini
   • R. Abbiati
   • V. Mandelli

   OriginalPaper Pages: 311 - 316

3. Unaltered glucagon secretion after seven days of sulphonylurea administration in normal subjects

   • J. Marco
   • I. Valverde

   OriginalPaper Pages: 317 - 319

4. Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C¹⁴-glipizide, a new antidiabetic

   • H. A. E. Schmidt
   • M. Schoog
   • E. Winkler

   OriginalPaper Pages: 320 - 330

5. Pharmacokinetics of glipizide in man: Influence of renal insufficiency

   • L. Balant
   • G. Zahnd
   • J. Fabre

   OriginalPaper Pages: 331 - 338

6. Glipizide, a new oral antidiabetic agent (report of a controlled clinical study in Sweden)

   • A. Johannessen
   • S. E. Fagerberg

   OriginalPaper Pages: 339 - 347

7. Clinical study with glipizide, a new oral antidiabetic drug

   • G. Persson

   OriginalPaper Pages: 348 - 350

8. Glipizide versus tolbutamide in maturity-onset diabetes, an open comparative study

   • K. Fuchs

   OriginalPaper Pages: 351 - 355

9. Clinical experience with glipizide in the treatment of mostly complicated diabetes

   • A. Masbernard
   • C. Giudicelli
   • J. Massey

   OriginalPaper Pages: 356 - 363

10. An open comparative study of the efficacy and tolerance of a new antidiabetic agent: Glipizide

    • I. De Leeuw
    • H. De Baere
    • H. Verhaegen

    OriginalPaper Pages: 364 - 366